New Education Series Designed to Remove Barriers to Mental Health Treatment and Recovery
This summer, the FDA announced the final steps in eliminating the Clozapine Risk Evaluation and Mitigation Strategy (REMS) regulations by modifying labeling to reflect their February 24, 2025, decision to eliminate the REMS program. Terminating REMS is expected to help patients more easily access clozapine and marks a pivotal moment…more.
















